Evidence map›Paper›PMID 35470188›Full record

Trial reportBMJ open2022

Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial.

Yun Liu, Narasimha M Beeraka, Junqi Liu, Kuo Chen, Bo Song, Zhang Song, Jianchao Luo, Yang Liu, Anping Zheng, Yanhui Cui and 15 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 15 institutions in 3 countries.

Yun Liu *Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Narasimha M Beeraka *Cancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junqi LiuCancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Kuo ChenCancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Bo SongDepartment of Oncology, The Xinyang Central Hospital, Xinyang, China.
Zhang SongCancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jianchao LuoDepartment of Oncology, The Henan Provincial People's Hospital, Zhengzhou, China.
Yang LiuDepartment of Radiation Oncology, The Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, China.
Anping ZhengDepartment of Radiation Oncology, Anyang Cancer Hospital, Anyang, China.
Yanhui CuiDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China.
Yang WangDepartment of Radiation Oncology, The Nanyang Central Hospital, Nanyang, China.
Zhenhe JiaDepartment of Oncology, The Xixia County People's Hospital, xixia, China.
Xiangyu SongDepartment of Radiation Oncology, The Linzhou People's Hospital, Linzhou, China.
Xiaohong WangDepartment of Radiation Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Hongqi WangDepartment of Radiation Oncology, General Hospital of Pingmei Shenma Medical Group Pingdingshan 467000, Pingmei, China.
Xuefeng QiDepartment of Radiation Oncology, The Linying County People's Hospital, Linying, China.
Jinshan RenDepartment of Radiation Oncology, The First Affiliated Hospital of Nanyang Medical College, Nanyang, China.
Liping WuDepartment of Radiation Oncology, The Xinxiang Central Hospital, Xinxiang, China.
Jixing CaiDepartment of Radiation oncology, the Linzhou Cancer Hospital, 456550, P.R, Linzhou, People's Republic of China.
Xainying FangDepartment of Oncology, The Xinyang Central Hospital, Xinyang, China.
Xin WangCancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mikhail Y SinelnikovDepartment of Human Anatomy, Sechenov University, Moskva, Moskva, Russian Federation.
Vladimir N NikolenkoDepartment of Human Anatomy, Sechenov University, Moskva, Moskva, Russian Federation.
M V GreeshmaCenter of Excellence in Molecular Biology and Regenerative Medicine (CEMR), Department of Biochemistry, JSS Academy of Higher Education and Research (JSS AHER), JSS Medical College, Mysuru, Karnataka, India.
Ruitai FanCancer Center, Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China fccfanrt@zzu.edu.cn.ORCID 0000-0003-3401-4315
First Affiliated Hospital of Zhengzhou University · CNFirst Affiliated Hospital of Henan University of Science and Technology · CNJSS Academy of Higher Education and Research · INLinzhou Cancer Hospital · CNSechenov University · RUUniversity of Science and Technology of China · CNXinyang Central Hospital · CNAnyang Tumor Hospital · CNFirst Affiliated Hospital of Xinxiang Medical University · CNHenan Provincial People's Hospital · CNLinyi People's Hospital · CNNanyang Institute of Technology · CNNanyang Medical College · CNThe People's Hospital of LinXia · CNXinxiang Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOesophageal squamous cell carcinoma (OSCC) is one of the most commonly occurring devastating tumours worldwide, including in China. To date, the standard care of patients with stage IV OSCC is systemic chemotherapy and palliative care, which results in poor prognosis. However, no consensus has been established regarding the role of radiotherapy in targeting the primary tumour in patients with stage IVa OSCC. Thus, the aim of this study is to assess the effectiveness of primary radiotherapy combined with S-1 and nedaplatin (NPD) chemotherapy in the patients with stage IV OSCC. METHODS AND ANALYSIS: The study is a multicentre, open-label, randomised controlled trial. A total of 180 eligible patients with stage IV OSCC will be randomised into a study group (90 patients) and a control group (90 patients). Patients in the study group will receive radiotherapy to the primary tumour at a dose of 50.4 Gy combined with 4-6 cycles of S-1 and NPD chemotherapy. In the control group, patients will only receive 4-6 cycles of S-1 and NPD chemotherapy. The primary and secondary outcomes will be measured. The differences between the two groups will be statistically analysed with regard to overall survival, the progression-free survival and safety. All outcomes will be ascertained before treatment, after treatment and after the follow-up period.The results of this study will provide evidence on the role of radiotherapy in patients with stage IV OSCC in China, which will show new options for patients with advanced oesophageal cancer. ETHICS AND DISSEMINATION: This study was approved by the Institutional Ethics Committee of The First Hospital Affiliated of Zhengzhou University (approval number: SS-2018-04).

trial registrationThe trial has been registered at the Chinese Clinical Trial Registry (ChiCTR1800015765) on 1 November 2018; retrospectively registered, http://www.chictr.org.cn/index.aspx.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaChemoradiotherapyHumansOrganoplatinum CompoundsnedaplatinOrganoplatinum CompoundsONCOLOGYRADIOTHERAPYRespiratory tract tumours

Identifiers

PMID35470188
PMCPMC9039379
OpenAlexW4224948656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.